WO2002053091A3 - Association medicamenteuse d'une biguanine (metformine) et d'arginine - Google Patents

Association medicamenteuse d'une biguanine (metformine) et d'arginine Download PDF

Info

Publication number
WO2002053091A3
WO2002053091A3 PCT/FR2001/004236 FR0104236W WO02053091A3 WO 2002053091 A3 WO2002053091 A3 WO 2002053091A3 FR 0104236 W FR0104236 W FR 0104236W WO 02053091 A3 WO02053091 A3 WO 02053091A3
Authority
WO
WIPO (PCT)
Prior art keywords
function
bond
cleaving
covalent
restoring
Prior art date
Application number
PCT/FR2001/004236
Other languages
English (en)
Other versions
WO2002053091A2 (fr
Inventor
Jean-Robert Rapin
Dominique Halbitte
Original Assignee
Dospharma
Jean-Robert Rapin
Dominique Halbitte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dospharma, Jean-Robert Rapin, Dominique Halbitte filed Critical Dospharma
Priority to JP2002554042A priority Critical patent/JP2004517106A/ja
Priority to CA002435483A priority patent/CA2435483A1/fr
Priority to EP01990622A priority patent/EP1446161A2/fr
Priority to NZ527207A priority patent/NZ527207A/en
Priority to US10/465,994 priority patent/US20040058854A1/en
Publication of WO2002053091A2 publication Critical patent/WO2002053091A2/fr
Publication of WO2002053091A3 publication Critical patent/WO2002053091A3/fr
Priority to US11/879,505 priority patent/US20080021015A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Abstract

Utilisation en tant que médicament d'un composé actif de formule générale A'---V'---C', capable de restituer au moins l'entité A par clivage in-vivo des liaisons correspondantes entre A' et V', et optionnellement capable de restituer également les entités V et C par clivage in-vivo de la liaison V'---C' ou V'-C' étant spécifié que: V est un composé biogénique de vectorisation, de formule générale X-R-Y, dans laquelle, *R représente une chaîne hydrocarbonée de 2 à 10 atomes de carbone, aliphatique, cyclique, ou alicyclique, saturée ou non, éventuellement substituée par des groupes alkyles en C1 à C5, et/ou des groupes hydroxyles, *X et Y sont chacun une fonction libre acide, amine, ou alcool. A et C sont deux principes actifs respectivement différents, dont l'un comprend une fonction chimique complémentaire de la fonction X, susceptible de réagir avec cette dernière pour donner une liaison clivable in vivo, ionique A'---V' ou covalente A'-V', et dont l'autre comprend une fonction chimique complémentaire de la fonction Y, susceptible de réagir avec cette dernière pour donner une liaison clivable in vivo, ionique, V'---C' ou covalente V'-C'.
PCT/FR2001/004236 2000-12-29 2001-12-31 Association medicamenteuse d'une biguanine (metformine) et d'arginine WO2002053091A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002554042A JP2004517106A (ja) 2000-12-29 2001-12-31 有効成分を生体内で回復させる化合物の薬剤としての使用
CA002435483A CA2435483A1 (fr) 2000-12-29 2001-12-31 Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs
EP01990622A EP1446161A2 (fr) 2000-12-29 2001-12-31 Association medicamenteuse d'une biguanine (metformine) et d'arginine
NZ527207A NZ527207A (en) 2000-12-29 2001-12-31 Use as medicine of a compound restoring active principles in vivo
US10/465,994 US20040058854A1 (en) 2000-12-29 2001-12-31 Use as medicine of a compound restoring active principles in vivo
US11/879,505 US20080021015A1 (en) 2000-12-29 2007-07-18 Use as medicine of a compound restoring active principles in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017331A FR2818908B1 (fr) 2000-12-29 2000-12-29 Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs
FR00/17331 2000-12-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/879,505 Continuation US20080021015A1 (en) 2000-12-29 2007-07-18 Use as medicine of a compound restoring active principles in vivo

Publications (2)

Publication Number Publication Date
WO2002053091A2 WO2002053091A2 (fr) 2002-07-11
WO2002053091A3 true WO2002053091A3 (fr) 2004-06-10

Family

ID=8858429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/004236 WO2002053091A2 (fr) 2000-12-29 2001-12-31 Association medicamenteuse d'une biguanine (metformine) et d'arginine

Country Status (9)

Country Link
US (2) US20040058854A1 (fr)
EP (1) EP1446161A2 (fr)
JP (1) JP2004517106A (fr)
CA (1) CA2435483A1 (fr)
FR (1) FR2818908B1 (fr)
NZ (1) NZ527207A (fr)
RU (1) RU2003123490A (fr)
WO (1) WO2002053091A2 (fr)
ZA (1) ZA200207757B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868653A2 (fr) * 2005-04-12 2007-12-26 PSivida Inc. Combinaisons d'inhibiteurs de hmgcoa reductases et leurs utilisations
WO2007016306A2 (fr) * 2005-08-01 2007-02-08 Psivida Inc. Composes inhibiteurs de l'enzyme de conversion de l'angiotensine- inhibiteurs de la hmgcoa reductase
EP2712913B1 (fr) * 2012-09-28 2016-03-30 The Procter and Gamble Company Système de structuration externe pour composition détergente liquide

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696740A1 (fr) * 1992-10-13 1994-04-15 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
GB2278843A (en) * 1993-06-07 1994-12-14 British Tech Group Anti-cancer compounds
WO1995020567A1 (fr) * 1994-01-28 1995-08-03 University Of Kentucky Research Foundation Co-medicaments utilises comme procede d'apport regule de medicaments
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
WO1999055320A1 (fr) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Composition orale comprenant un biguanide et un acide organique
FR2796551A1 (fr) * 1999-07-23 2001-01-26 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
WO2002026220A2 (fr) * 2000-09-25 2002-04-04 University Of North Carolina At Chapel Hill Conjugues taxoides utiles entant qu'agents antimitotiques et antitumoraux

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US6075121A (en) * 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5240693A (en) * 1991-05-01 1993-08-31 University Of New Mexico Image enhancement by coadministration of biomodulators and structurally modified imaging agents
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696740A1 (fr) * 1992-10-13 1994-04-15 Dospharma Sa Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
GB2278843A (en) * 1993-06-07 1994-12-14 British Tech Group Anti-cancer compounds
WO1995020567A1 (fr) * 1994-01-28 1995-08-03 University Of Kentucky Research Foundation Co-medicaments utilises comme procede d'apport regule de medicaments
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
WO1999055320A1 (fr) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Composition orale comprenant un biguanide et un acide organique
FR2796551A1 (fr) * 1999-07-23 2001-01-26 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
WO2002026220A2 (fr) * 2000-09-25 2002-04-04 University Of North Carolina At Chapel Hill Conjugues taxoides utiles entant qu'agents antimitotiques et antitumoraux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARFELLA R ET AL: "METFORMIN IMPROVES HEMODYNAMIC AND RHEOLOGICAL RESPONSES TO L-ARGININE IN NIDDM PATIENTS", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 19, no. 9, September 1996 (1996-09-01), pages 934 - 939, XP001036613, ISSN: 0149-5992 *

Also Published As

Publication number Publication date
ZA200207757B (en) 2004-07-26
RU2003123490A (ru) 2005-01-20
US20080021015A1 (en) 2008-01-24
WO2002053091A2 (fr) 2002-07-11
JP2004517106A (ja) 2004-06-10
EP1446161A2 (fr) 2004-08-18
NZ527207A (en) 2006-04-28
CA2435483A1 (fr) 2002-07-11
US20040058854A1 (en) 2004-03-25
FR2818908A1 (fr) 2002-07-05
FR2818908B1 (fr) 2004-04-02

Similar Documents

Publication Publication Date Title
EP1302458A4 (fr) Derives d'ester
DE50014571D1 (de) Träger-pharmaka-konjugate
WO2004087635A3 (fr) Melanges de composes ayant au moins deux liaisons doubles et leur utilisation
BG101095A (en) Polyethyleneglycolizing reagents and compounds produced by them
KR940005652A (ko) 담즙산 유도체, 이의 제조방법 및 약제로서의 이들 화합물의 용도
TW200632551A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
CA2309004A1 (fr) Compose adhesif et sa methode de production
DK0751144T3 (da) Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs
NO20041494L (no) Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form
DE69329735D1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
BR0114252A (pt) Derivados de nitrosodifenilamina
ATE414674T1 (de) Kreisel und verfahren zur dessen herstellung
CA2418770A1 (fr) Compose acylacetonitrile, processus de preparation, et acaricide contenant ce compose
WO2007058568A3 (fr) Sels et melanges d'acide 9-oxoacridine-10-acetique et de 1-alkylamino-1-desoxypolyols, compositions pharmaceutiques les contenant, et methodes de traitement associees
EP1329218A4 (fr) Agents preventifs/remedes destines a l'hypertension portale
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
WO2002007770A3 (fr) Conjugues polymeres d'agents antitumoraux
WO2002053091A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
DE4191848D2 (de) Cyclopentanderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE69132656D1 (de) Organische polymerverbindung und ihre herstellung
EP0790252A4 (fr) Derive d'acide fumarique et son polymere
EP1310490A4 (fr) Antagoniste de gpr14
NO953992L (no) Fremgangsmåte for fremstilling av aminometanfosforsyre
IE780397L (en) Guanines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 554042

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2002/07757

Country of ref document: ZA

Ref document number: 200207757

Country of ref document: ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001990622

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2435483

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 527207

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002229840

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10465994

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001990622

Country of ref document: EP